LONDON: Neurocrine Biosciences, a neuroscience-focused biopharmaceutical company, has agreed to acquire Diurnal Group. The acquisition values the entire issued and to be issued ordinary share capital of Diurnal at approximately £48.3 million. Under the terms of the acquisition, Diurnal shareholders shall be entitled to receive 27.5 pence in cash for each Diurnal share. Neurocrine Biosciences…
Month: August 2022
Dechra Pharmaceuticals has acquired Med-Pharmex Inc
LONDON: Dechra Pharmaceuticals has acquired Med-Pharmex Inc. The total consideration paid was US$260.0 million on a debt-free and cash-free basis, and was subject to normal closing adjustments. Med-Pharmex is a leading veterinary pharmaceutical manufacturer based in Pomona, California. The acquisition will be funded from existing available debt resources. Dechra has known Med-Pharmex for a number…
Farxiga reduced risk of CV death or worsening HF
LONDON: Detailed results from the DELIVER Phase III trial showed AstraZeneca’s Farxiga (dapagliflozin) significantly reduced the composite of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (EF), compared to placebo. The results were presented today at the European Society of Cardiology Congress 2022 in…
Spectral MD Awarded an Additional $8.2M of Funding from BARDA
LONDON: Spectral MD Holdings, a predictive analytics company with proprietary AI and optical technology for faster and more accurate treatment decisions in wound care, has been awarded $8.2 million in additional funding by the US Biomedical Advanced Research and Development Authority (BARDA). This funding supplements the original award announced on September 6, 2021, and brings…
nanosynth signs joint development agreement in cosmetics market
LONDON: nanosynth, the AIM quoted company specialising in the synthesis and application of nanoparticles to create new and improve existing products, have entered into a joint development agreement with a global wellness company for their first project in the cosmetics market. It is anticipated that the development programme will run for 12 months and involve…
Artec Aqua signs agreement for a land-based Atlantic salmon grow-out facility on Iceland
OSLO, NORWAY: Endúr ASA’s wholly owned subsidiary Artec Aqua AS has today signed an agreement with Geo Salmo ehf as turnkey supplier for a land-based grow-out facility for Atlantic salmon on Iceland. The facility will be located in Þorlákshöfn, close to Reykjavik on Iceland. The production capacity for the complete facility will be 18,900 tonnes…
Why consumers prefer to pay online with cards rather than Cash on Delivery
Security of payment facility offered on a merchant website is the top reason consumers would choose to pay online with their cards rather than Cash on Delivery (COD), according to the 2022 Stay Secure by Visa and Daraz. Guarantees their payment data would be protected (maintaining privacy) was second (63% of consumers) while price of…
Live Verdure Ltd will acquire Edible Beauty
SYDNEY: Live Verdure Ltd (LV1) will acquire Edible Beauty for a consideration of $1m (consisting of 75% in cash and 25% in shares), with deferred payments based on future revenue. Live Verdure Ltd is an Australian Direct to Consumer (DtoC) plant-based food, nutraceutical and skincare company comprising a portfolio of brands with a range of…
Ultomiris approved in Japan gMG
LONDON: Ultomiris (ravulizumab) has been approved in Japan for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin therapy (IVIg) or plasmaphaeresis. Japan’s Pharmaceuticals and Medical Devices Agency also indicated that Ultomiris can be considered for patients who cannot receive high-dose…
Tagrisso approved in Japan for early lung cancer
LONDON: AstraZeneca‘s Tagrisso (osimertinib) has been approved in Japan for the adjuvant treatment of patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after surgery. This approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the global ADAURA Phase III trial. While up to 30% of all patients…